Common chemo drug activates dormant virus in Burkitt's
Researchers out of the University of South Carolina at Chapel Hill (UNC) believe they have uncovered a mechanism that, when properly exploited for treatment, can treat both an aggressive form of non-Hodgkin's lymphoma as well as the common virus known to cause it.
BLOOD CANCER SUBTYPE(S) IN QUESTION
Burkitt's lymphoma and EBV, the Epstein-Barr virus (EBV is extremely widespread, but typically lies dormant within cancer cells).
COHORT
21 patients between 5-15 years old diagnosed with EBV-related Burkitt's lymphoma and receiving cyclophosphamide.
RESEARCH FINDINGS
The researchers discovered that in children with Burkitt's, the common chemotherapy agent cyclophosphamide "simultaneously triggered an active EBV infection. The increased replication of EBV in cancer tissue makes these cells more susceptible to the antiviral drugs that kill cells containing replicating virus", like ganciclovir and valacyclovir, two already widely-used antiviral drugs.
The discovery shows scientists for the first time just how closely cancers and viruses interact in humans.
PUBLICATION & SOURCES
This study was published in the journal Clinical Cancer Research.
Source: UNC press release
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
